SCHEDULE 4
PART I CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27
F15
A liquid formulation—
a
containing a botanical extract of cannabis—
i
with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and
ii
where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,
b
which is dispensed through a metered dose pump as a mucosal mouth spray, and
c
which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010